The American Journal of Managed Care

Subcutaneous Amivantamab Allows for Potential Increases in Adherence, Treatment Options: Martin Dietrich, MD, PhD

The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.

Precision’s Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

Equity Insider News Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion ...
Medscape

FDA OKs Subcutaneous Mosunetuzumab for Follicular Lymphoma

The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.
The American Journal of Managed Care

FDA Approves Subcutaneous Mosunetuzumab for R/R Follicular Lymphoma

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

Genentech's subcutaneous Lunsumio gains FDA approval

The US FDA has approved a subcutaneous version of Roche (RHHBY)-owned Genentech's follicular lymphoma treatment, Lunsumio ...
Targeted Oncology

Dosage, IV Administration Considered in Use of Axatilimab for cGVHD

During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease. A significant number of patients who develop chronic graft-vs-host ...
Targeted Oncology

FDA Approves Subcutaneous Mosunetuzumab in Follicular Lymphoma

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...

FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ ...